Syncom Formulations (India) Reports Strong Financial Performance in Q1 2024

Aug 13 2024 04:35 PM IST
share
Share Via
Syncom Formulations (India) has reported a strong financial performance for the quarter ended June 2024, with a significant improvement in its score from 2 to 20. The company's ability to manage interest payments, increasing net sales, and growing profitability are key factors contributing to this positive trend. However, the company needs to address its slowing debtors turnover ratio. With a 'Buy' call from MarketsMojo, investors can expect good returns in the near future.

Syncom Formulations (India), a smallcap pharmaceutical company, has recently declared its financial results for the quarter ended June 2024. The company has shown a very positive performance in this quarter, with its score improving from 2 to 20 in the last 3 months.

One of the key factors contributing to this positive performance is the company's ability to manage its interest payments. The operating profit to interest ratio for this quarter is the highest at 26.82 times and has been growing each quarter in the last five quarters. This shows that the company's financial health is improving and it is able to handle its interest payments effectively.

Another positive aspect is the company's net sales, which have been consistently growing each quarter in the last five quarters. The net sales for this quarter are the highest at Rs 87.26 crore, indicating a very positive sales trend in the near term.

The profit before tax (PBT) less other income for this quarter is also the highest at Rs 8.76 crore and has been growing each quarter in the last five quarters. This shows that the company's profitability is increasing and it is able to generate higher earnings for its shareholders.

In terms of debt management, Syncom Formulations has been reducing its borrowing as compared to its equity capital. The debt-equity ratio for the last five half yearly periods is the lowest at 0.25 times, indicating a healthy financial position.

However, one area of concern is the company's debtors turnover ratio, which has slowed down in the last five half yearly periods. This means that the company's pace of settling its debtors has decreased. This is something that the company needs to address in order to maintain its positive financial performance.

Overall, Syncom Formulations (India) has shown a very positive financial performance in the quarter ended June 2024. With a 'Buy' call from MarketsMOJO, the company seems to be on the right track and investors can expect good returns in the near future.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Why is Syncom Formul. falling/rising?
Nov 25 2025 01:16 AM IST
share
Share Via
Is Syncom Formul. overvalued or undervalued?
Nov 19 2025 08:09 AM IST
share
Share Via
Is Syncom Formul. overvalued or undervalued?
Nov 17 2025 08:10 AM IST
share
Share Via
Is Syncom Formul. overvalued or undervalued?
Nov 16 2025 08:09 AM IST
share
Share Via
Is Syncom Formul. overvalued or undervalued?
Nov 15 2025 08:10 AM IST
share
Share Via